Health Care · Pharmaceutical Preparations

VRDN Viridian Therapeutics, Inc.\DE SEC Filings & Insider Trading Activity 2026

company
CIK 1590750127 filings
Russell 2000

VRDN at a glance

Viridian Therapeutics, Inc.\DE (VRDN, SEC CIK 1590750) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as August 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Viridian Therapeutics, Inc.\DE (VRDN) reported revenue of $70.8 million (up 23359.9% from FY2024) and a net loss of $342.6 million.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Viridian Therapeutics, Inc.\DE (VRDN) shares worth $785.6 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Tousignant Jennifer on August 19, 2026 of 10,000 shares at $24.50 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$70.8M
+23359.9% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
30 funds
$785.6M · +3 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 7.01 · Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core biopharma focus on autoimmune and rare diseases, emphasizing best-in-class therapies for thyroid eye disease (TED) and related conditions
  • New subcutaneous IGF-1R antibody elegrobart in pivotal phase 3 (REVEAL-1/2) for TED with potential auto-injector, complementing intravenous veligrotug
  • Strategic shift to commercial launch prep for veligrotug post-BLA acceptance (Priority Review, PDUFA June 30, 2026) and building U.S. commercial infrastructure
  • Over 300 patients enrolled in safety databases for veligrotug and elegrobart exceeding targets; phase 3 TED trial enrollment higher than anticipated (>330 total)
  • Introduction of TSHR inhibitor program targeting Graves’ disease and TED, with IND planned for Q4 2026, expanding pipeline beyond IGF-1R and FcRn inhibitors

Risk Factors

  • Regulatory risk: FDA may require additional patients or steps for veligrotug and elegrobart phase 3 trials, risking approval delays or denials
  • Geopolitical exposure: Clinical trial operations in Israel and China vulnerable to adverse regulatory actions or unrest impacting progress
  • Operational vulnerability: Dependence on third-party CDMOs and CROs for manufacturing and trial conduct risks delays or non-compliance (cGMP, cGCP)
  • Competitive risk: Delays or failures in clinical trials could allow competitors to market similar therapies earlier, impairing commercial prospects
  • Financial risk: Net loss $342.6M in 2025, cash $874.7M enabling operations ~12 months; inability to raise capital may force program scale-backs or bankruptcy

Management Discussion & Analysis

  • Revenue $70.8M in 2025 vs $0.3M in 2024; increase driven by $70M upfront license payment from Kissei and related party collaborations
  • Research & Development expenses $338.9M in 2025 vs $238.3M in 2024; TED portfolio R&D up $78.3M, driven by phase 3 trials and milestone fees
  • Selling, General & Administrative expenses $95.3M in 2025 vs $61.1M in 2024; increased by $34.2M to support commercial infrastructure buildout
  • Net loss $342.6M in 2025 vs $269.9M in 2024; loss widened by $72.7M reflecting increased R&D and SG&A spend

AI summary of the VRDN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $24.7M, versus $70.0M license revenue in Q3 2025, driven by new veligrotug sales
  • Net loss $101.2M vs $34.6M YoY, with cost of revenues $1.5M and SG&A $57.6M
  • TED R&D largest at $23.9M, down $31.3M YoY; other research programs increased $5.9M to $7.2M
  • Cash, equivalents and marketable securities $955.2M; operating cash use $317.8M through nine months
  • Outlook: elegrobart BLA expected Q1 2027; macroeconomic uncertainty, tariffs, inflation and supply-chain risks 񟿿

Risk Factors

  • Newly emphasized regulatory risk: BIOSECURE Act enacted December 2025, potentially restricting WuXi services and U.S. government contracting
  • Most material update: FDA disruption risk from federal shutdowns and workforce reductions, threatening BLA reviews and inspections
  • Operational risk: Single-sourced manufacturing with WuXi for veligrotug and product candidates, exposing supply continuity
  • Competitive risk: More than 20 FcRn indications in development, increasing potential competition for the pipeline
  • Financial risk: $250.0 million 1.75% convertible senior notes due 2032, requiring future cash servicing or refinancing

AI summary of the VRDN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Phase 1 data announced for VRDN-008, a half-life extended bispecific FcRn inhibitor
  • Results come from healthy volunteers, providing early safety, pharmacokinetic and dosing evidence

Item 8.01: Other Events

  • VRDN-008 achieved 74% peak IgG reduction in six healthy volunteers, supporting potential FcRn inhibitor efficacy
  • Half-life 15 to 18 days, enabling targeted Q8W subcutaneous dosing

Item EX-99.1: Item EX-99.1

  • Phase 1 supports VRDN-008’s potential differentiation: 74% peak IgG reduction sustained through 8 weeks
  • Half-life 15–18 days, up to 6x longer than first-generation Fc fragments
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Viridian’s press release reports financial results for the quarter ended September 30, 2026
  • Investor focus: quarterly cash position, operating expenses, pipeline progress, and guidance in the accompanying release

Item EX-99.1: Item EX-99.1

  • Lumvoa Q3 net product revenue $24.7M, with more than 100 patients on therapy, establishing initial commercial traction in TED
  • Permanent CMS J-code J3242 effective January 1, 2027, potentially supporting reimbursement and broader Lumvoa adoption
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Lumvoa FDA-approved June 26 and launched immediately, transitioning Viridian into commercial operations with early physician and payer traction
  • Sales team engaged 95% of 2,000 core prescribing physicians; first doses administered in July, supporting initial demand but not yet revenue scale

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced for the quarter ended June 30, 2026
  • Investor-relevant figures and management commentary contained in the August 6, 2026 press release

AI summaries of VRDN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for VRDN

Don't miss the next VRDN filing

  • Alerts as it files. A push when VRDN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut VRDN, by share count.
  • Ask anything. An AI agent that reads every VRDN filing and answers with sources.

VRDN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Tousignant JenniferMAug 19, 2026$14.41
Tousignant JenniferSellAug 19, 2026$24.50
Tousignant JenniferMAug 19, 2026-
Tousignant JenniferSellAug 19, 2026$24.50
Tripuraneni RadhikaMAug 14, 2026-
Tripuraneni RadhikaMAug 14, 2026$13.21
CAIN CHRISTOPHER W.AJul 1, 2026-
Ajer Jeffrey RobertAJul 1, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$302K$70.8M
Operating Income-$254.4M-$299.0M-$363.4M
Net Income-$237.7M-$269.9M-$342.6M
Op. Margin--99018.2%-512.9%
Net Margin--89387.1%-483.6%
Balance Sheet
Total Assets$490.4M$742.4M$899.4M
Equity$442.0M$671.6M$722.2M
ROE-53.8%-40.2%-47.4%
Per Share
EPS$-5.31--
Cash Flow
Operating CF--$232.3M-$276.4M
CapEx$898K$511K$495K

Source: XBRL data in Viridian Therapeutics, Inc.\DE (VRDN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate VRDN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
VRDN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$785.6M
Q2 202627$987.5M
Q1 202630$933.1M
Q4 202524$1.33B
Q3 202524$676.5M
Q2 202524$452.7M
Q1 202523$330.8M
Q4 202420$457.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

VRDN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 9, 2026Analysis-
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
4Aug 20, 2026--
SC 13GAug 20, 2026-
4Aug 18, 2026--
SC 13GAug 14, 2026-
SC 13GAug 7, 2026-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
8-KJun 29, 2026Analysis-
SC 13GJun 26, 2026-
8-KJun 3, 2026Analysis
8-KMay 28, 2026Analysis
8-KMay 26, 2026Analysis
SC 13GMay 15, 2026-
4May 13, 2026-
8-KMay 11, 2026Analysis
SC 13GMay 8, 2026-

Related Health Care companies

All Health Care →

VRDN SEC filings: frequently asked questions

Which institutions hold VRDN stock?

As of September 30, 2026, the largest Viridian Therapeutics, Inc.\DE (VRDN) holders among the 13F filers tracked by SignalX were BlackRock ($192.1 million), T. Rowe Price Group ($105.5 million), State Street Corp ($100.4 million), Vanguard Capital Management LLC ($97.9 million), Vanguard Portfolio Management LLC ($49.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was VRDN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Viridian Therapeutics, Inc.\DE (VRDN) reported revenue of $70.8 million (up 23359.9% from FY2024) and a net loss of $342.6 million. The figures come from the XBRL data in the 10-K.

What are the main risks in VRDN's latest 10-K?

In the 10-K filed February 26, 2026, Viridian Therapeutics, Inc.\DE (VRDN) flagged: Regulatory risk: FDA may require additional patients or steps for veligrotug and elegrobart phase 3 trials, risking approval delays or denials. Geopolitical exposure: Clinical trial operations in Israel and China vulnerable to adverse regulatory actions or unrest impacting progress. (AI summary of the Risk Factors section.)

What did VRDN report in its latest 8-K?

Viridian Therapeutics, Inc.\DE (VRDN) filed an 8-K on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Phase 1 data announced for VRDN-008, a half-life extended bispecific FcRn inhibitor.

What are the latest VRDN SEC filings?

Viridian Therapeutics, Inc.\DE (VRDN) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on August 20, 2026.

What is VRDN's SEC CIK number?

Viridian Therapeutics, Inc.\DE (VRDN)'s SEC Central Index Key (CIK) is 1590750. EDGAR lists every VRDN filing under that number.

Ask anything about VRDN

The research agent reads VRDN's filings, financials, insider trades and 13F holders, then answers with sources.